Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations, a rare brain cancer mainly affecting young people. The ...

"I sit here just knowing that my babies are a part of me on a cellular level and that healed something in me when I heard ...

The ASX had fallen 0.64% in the first hour, with all 11 sectors in the red. CHM fielded strong clinical results in a Phase 1b ...

Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an update.

Genetic engineering technologies allow for the creation of custom-made cells that can have transformative effects on human health. This is best exemplified by chimeric antigen receptor (CAR) T-cells.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an ...

Five-year collaboration supports consistent clinical supply for Phase 1A/1B GI cancer study PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therap ...

Chimeric antigen receptor-T (CAR-T) cell therapy represents a major breakthrough in cancer immunotherapy, providing remarkable clinical benefits for ...

The latest update is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).